NOVO B NOVO NORDISK A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonChristina Law 
2 Reason for the notification 
a)Position/statusMember of the Board of Directors 
b)Initial notification/AmendmentInitial notification 
3 Details of the issuer 
a)NameNovo Nordisk A/S 
b)LEI549300DAQ1CVT6CXN342 
4 Details of the transaction(s) 
a)Description of the financial instrument,

type of instrument,
ADRs



 
 Identification codeNVO 
b)Nature of the transactionPurchase of ADRs 
c)







Price(s) and volume(s)







 Price(s)Volume(s)  
 DKK 349.06952 ADRs  
 DKK 349.04598 ADRs  
   DKK 349.03800 ADRs  
d)Aggregated information
  • Aggregated volume
  • Price




2,350 ADRs

DKK 820,252.49
 
e)Date of the transaction2025-08-18 
f)Place of the transactionNew York Stock Exchange 



Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit  , , , and .



Contacts for further information

Media: 
Ambre James-Brown







Liz Skrbkova (US)







Investors: 
Jacob Martin Wiborg Rode







Sina Meyer







Max Ung







Christoffer Sho Togo Tullin







Alex Bruce







Frederik Taylor Pitter









Attachment



EN
19/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NOVO NORDISK A/S

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of th...

 PRESS RELEASE

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based...

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 12 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of th...

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the...

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch